IONS Ionis Pharmaceuticals, Inc. Stock Quote

IONS [NASD]

Index	-	P/E	-	EPS (ttm)	-3.23	Insider Own	0.20%	Shs Outstand	139.96M	Perf Week	-1.34%
Market Cap	7.94B	Forward P/E	-	EPS next Y	-1.18	Insider Trans	-58.55%	Shs Float	132.81M	Perf Month	-7.94%
Income	-451.30M	PEG	-	EPS next Q	-0.45	Inst Own	88.30%	Short Float	5.98%	Perf Quarter	8.16%
Sales	729.30M	P/S	10.89	EPS this Y	-257.00%	Inst Trans	0.98%	Short Ratio	7.26	Perf Half Y	4.75%
Book/sh	6.03	P/B	9.17	EPS next Y	15.40%	ROA	-15.50%	Target Price	65.47	Perf Year	5.74%
Cash/sh	13.18	P/C	4.20	EPS next 5Y	-	ROE	-36.40%	52W Range	39.32 - 64.37	Perf YTD	-2.19%
Dividend	-	P/FCF	9924.97	EPS past 5Y	-34.40%	ROI	-29.30%	52W High	-15.81%	Beta	1.19
Dividend %	-	Quick Ratio	3.60	Sales past 5Y	20.80%	Gross Margin	98.40%	52W Low	37.82%	ATR	2.45
Employees	757	Current Ratio	3.70	Sales Q/Q	-41.20%	Oper. Margin	-23.60%	RSI (14)	41.09	Volatility	4.70% 4.19%
Optionable	Yes	Debt/Eq	0.98	EPS Q/Q	-288.60%	Profit Margin	-61.90%	Rel Volume	0.69	Prev Close	55.30
Shortable	Yes	LT Debt/Eq	0.62	Earnings	Feb 24 BMO	Payout	-	Avg Volume	1.09M	Price	54.19
Recom	2.60	SMA20	-5.53%	SMA50	-7.23%	SMA200	-0.80%	Volume	139,866	Change	-2.01%

Mar-01-21

Upgrade

Barclays

Underweight → Equal Weight

$50 → $52

Dec-16-20

Initiated

UBS

Sell

$34

Dec-15-20

Upgrade

Cowen

Market Perform → Outperform

Sep-14-20

Resumed

JP Morgan

Neutral

$63

Sep-02-20

Initiated

The Benchmark Company

Hold

Jun-01-20

Resumed

Oppenheimer

Outperform

May-13-20

Initiated

RBC Capital Mkts

Outperform

$71

Mar-05-20

Initiated

Citigroup

Buy

$73

Dec-13-19

Initiated

Oppenheimer

Outperform

Nov-13-19

Initiated

BofA/Merrill

Buy

$70

Nov-07-19

Downgrade

Morgan Stanley

Equal-Weight → Underweight

$63 → $48

Sep-10-19

Upgrade

Bernstein

Mkt Perform → Outperform

Aug-08-18

Reiterated

Stifel

Hold

$48 → $47

Aug-07-18

Reiterated

Stifel

Hold

$55 → $48

May-08-18

Downgrade

Evercore ISI

Outperform → In-line

Oct-06-17

Resumed

Goldman

Sell

$30

Aug-17-17

Initiated

Evercore ISI

Outperform

$65

Aug-09-17

Reiterated

Stifel

Hold

$42 → $50

Mar-10-17

Downgrade

Goldman

Neutral → Sell

Dec-28-16

Reiterated

BMO Capital Markets

Outperform

$61 → $68

Mar-01-21 07:05AM	Ionis establishes new grant program to advance research and understanding of transthyretin amyloidosis PR Newswire
Feb-24-21 04:00PM	Ionis Pharmaceuticals, Inc. (IONS) Q4 2020 Earnings Call Transcript Motley Fool
07:00AM	Ionis reports fourth quarter and full year 2020 financial results and recent business achievements PR Newswire
Feb-19-21 07:05AM	Ionis to present at upcoming investor conferences PR Newswire
Feb-11-21 07:05AM	Ionis to hold 2020 financial results webcast PR Newswire
Feb-10-21 02:40AM	Has Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Impressive Stock Performance Got Anything to Do With Its Fundamentals? Simply Wall St.
Feb-08-21 09:59AM	New Strong Sell Stocks for February 8th Zacks
Jan-15-21 04:22PM	UBS Commercial Mortgage Trust 2017-C3 -- Moody's affirms seven classes of UBSCM 2017-C3 Moody's
04:19PM	UBS Commercial Mortgage Trust 2017-C3 -- Moody's affirms seven classes of UBSCM 2017-C3 Moody's
Jan-08-21 07:30AM	Biogen Announces First Patient Treated in RESPOND Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated With Zolgensma® (onasemnogene abeparvovec) GlobeNewswire
Jan-07-21 05:30PM	Ionis appoints Eugene Schneider, M.D., as executive vice president and chief clinical development officer PR Newswire +5.25%
Jan-05-21 07:05AM	Ionis to present at 39th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-23-20 02:03AM	Calculating The Fair Value Of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Simply Wall St.
Dec-17-20 06:30PM	Stanley T. Crooke, Ph.D., M.D, to retire from Ionis to focus on his scientific interests and n-Lorem Foundation PR Newswire
Dec-08-20 09:15PM	Ionis highlights achievements, commercial strategy and technology advancements at Investor Day PR Newswire
Dec-04-20 11:31AM	Why Is Ionis Pharmaceuticals (IONS) Up 4.6% Since Last Earnings Report? Zacks
Dec-02-20 07:05AM	Ionis to participate in virtual fireside chat at BMO 2020 Growth and ESG conference PR Newswire
Dec-01-20 05:10PM	Ionis announces initiation of the global Phase 3 BALANCE study for AKCEA-APOCIII-LRX in patients with familial chylomicronemia syndrome PR Newswire
07:05AM	Ionis to hold virtual investor day event PR Newswire
Nov-30-20 05:15PM	Ionis announces AstraZeneca's initiation of the Phase 2b clinical study of its antisense medicine targeting PCSK9 to lower LDL-cholesterol PR Newswire
Nov-23-20 05:15PM	Ionis announces third investigational antisense medicine to treat nonalcoholic steatohepatitis (NASH) enters development PR Newswire
Nov-13-20 07:05AM	Promising new data for Ionis' antisense medicine targeting PCSK9 presented at American Heart Association (AHA) Scientific Sessions 2020 PR Newswire
Nov-12-20 07:05AM	Ionis' pioneering antisense technology to be featured in multiple presentations at American Heart Association (AHA) Scientific Sessions 2020 PR Newswire
Nov-10-20 07:05AM	Ionis' antisense technology to be featured during virtual RNA at the Bench and Bedside II Conference PR Newswire
Nov-09-20 07:05AM	Ionis to present at upcoming virtual investor conferences PR Newswire
03:00AM	WAYLIVRA® (volanesorsen), the First and Only Therapy for Familial Chylomicronaemia Syndrome, an Ultra-Rare and Life-Threatening Condition, to Be Available on the NHS in Scotland Business Wire
Nov-08-20 08:28AM	Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Just Released Its Third-Quarter Earnings: Here's What Analysts Think Simply Wall St.
Nov-06-20 03:00AM	Ionis and Akcea Recognize FCS Awareness Day With Global Community Efforts to Celebrate Unsung Heroes Business Wire
Nov-05-20 09:57AM	Ionis (IONS) Misses Estimates for Q3 Earnings and Sales Zacks
Nov-04-20 08:31PM	Ionis Pharmaceuticals, Inc. (IONS) Q3 2020 Earnings Call Transcript Motley Fool
12:00PM	What's Behind Ionis Pharmaceuticals' Q3 Earnings Disappointment Motley Fool
08:25AM	Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Lags Revenue Estimates Zacks
07:24AM	Recap: Ionis Pharmaceuticals Q3 Earnings Benzinga
07:00AM	Ionis reports third quarter 2020 financial results and recent business achievements PR Newswire
06:42AM	Pfizer Initiates Phase 2b Study For Cardiovascular Treatment SmarterAnalyst
Nov-03-20 06:00PM	Ionis and Akcea announce that Pfizer has initiated a Phase 2b clinical study of vupanorsen (AKCEA-ANGPTL3-LRx) PR Newswire
Oct-30-20 07:00AM	Ionis and Akcea win prestigious Prix Galien Award for TEGSEDI® (inotersen) as Best Biotechnology Product PR Newswire
Oct-28-20 12:32PM	Analysts Estimate Ionis Pharmaceuticals (IONS) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-23-20 02:05PM	7 Unhealthy Biotech Stocks To Sell Before They Sicken Your Portfolio InvestorPlace
Oct-22-20 07:05AM	Ionis' third novel antisense medicine for ALS, its first designed to treat a broad ALS population, begins clinical trial PR Newswire
Oct-21-20 07:05AM	Ionis to hold third quarter 2020 financial results webcast PR Newswire
Oct-19-20 12:46PM	Is Ionis Pharmaceuticals a Buy? Motley Fool
Oct-15-20 07:05AM	Ionis antisense medicine being evaluated in an investigator-initiated clinical study of COVID-19 patients in Brazil PR Newswire
Oct-13-20 12:32PM	/C O R R E C T I O N -- Ionis Pharmaceuticals, Inc./ PR Newswire
Oct-12-20 09:00AM	Ionis Pharmaceuticals completes acquisition of Akcea Therapeutics PR Newswire
Oct-08-20 08:50AM	Ionis Pharmaceuticals (NASDAQ:IONS) Share Prices Have Dropped 25% In The Last Year Simply Wall St.
Oct-07-20 04:54PM	Hedge Funds Dipping Their Toes Into Ionis Pharmaceuticals, Inc. (IONS) Insider Monkey
Oct-02-20 11:18AM	Ionis' Alexander Disease Candidate Gets Orphan Drug Status Zacks
Oct-01-20 04:05PM	Ionis Chief Scientific Officer Frank Bennett receives Lifetime Achievement Award from Oligonucleotide Therapeutics Society PR Newswire
06:00AM	Ionis and Genuity Science announce agreement designed to rapidly translate genomic insights into therapeutics PR Newswire
Sep-30-20 04:05PM	Ionis treatment for Alexander disease receives orphan drug designation from U.S. FDA PR Newswire
Sep-21-20 06:45PM	SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Akcea Therapeutics, Inc. (Nasdaq -AKCA) ACCESSWIRE
Sep-04-20 11:31AM	Why Is Ionis Pharmaceuticals (IONS) Down 2.2% Since Last Earnings Report? Zacks
Sep-03-20 07:05AM	Ionis to present at upcoming virtual investor conferences PR Newswire
Sep-02-20 05:10PM	New England Journal of Medicine publishes study results evaluating Ionis antisense therapy in treatment of patients with hereditary angioedema PR Newswire
10:04AM	Are Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness? Simply Wall St.
Sep-01-20 10:14AM	Ionis to Acquire Remaining Stake in Akcea, Stocks Rally Zacks
05:34AM	(AKCA) Alert: Johnson Fistel Investigates Proposed Sale of Akcea Therapeutics; Is $18.15 a Fair Price? PR Newswire
Aug-31-20 08:10PM	SHAREHOLDER ALERT: WeissLaw LLP Investigates Akcea Therapeutics, Inc. PR Newswire
07:44PM	Why Akcea Therapeutics Stock Skyrocketed Today Motley Fool
06:56PM	SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Akcea Therapeutics, Inc. (NASDAQ:AKCA) ACCESSWIRE
06:55AM	Ionis Pharmaceuticals to acquire remaining stake in Akcea Therapeutics PR Newswire
Aug-29-20 04:00AM	Positive Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L(Rx)) Presented at ESC Congress 2020 PR Newswire
03:30AM	Positive Phase 2 Clinical Data of AKCEA-APOCIII-L(Rx) Presented at ESC Congress 2020 PR Newswire
Aug-26-20 07:05AM	Ionis Pharmaceuticals to hold cardio-renal franchise webcast PR Newswire
Aug-24-20 07:00AM	Akcea and Ionis to Present Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L (Rx) ) at ESC Congress 2020 PR Newswire
Aug-18-20 07:00AM	Akcea and Ionis to Present Phase 2 Results of AKCEA-APOCIII-L(Rx) in Late-Breaking Presentation at ESC Congress 2020 PR Newswire
Aug-13-20 07:00AM	Akcea Announces New Pricing and Reimbursement of WAYLIVRA® (volanesorsen) in Germany PR Newswire
Aug-06-20 09:21AM	Ionis (IONS) Q2 Loss Narrower Than Expected, Revenues Miss Zacks
Aug-05-20 08:55AM	Ionis Pharmaceuticals (IONS) Reports Q2 Loss, Misses Revenue Estimates Zacks
07:47AM	Ionis Pharmaceuticals: Q2 Earnings Insights Benzinga
07:00AM	Ionis reports second quarter 2020 financial results and recent business achievements PR Newswire
Jul-30-20 07:32PM	10 Biggest Biotechnology Companies Investopedia
Jul-29-20 12:33PM	Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Should You Buy? Zacks
Jul-27-20 02:39PM	Ionis Pharmaceuticals (NASDAQ:IONS) Could Easily Take On More Debt Simply Wall St.
Jul-22-20 07:05AM	Ionis Pharmaceuticals to hold second quarter 2020 financial results webcast PR Newswire
Jul-21-20 07:00AM	Akcea Therapeutics to Hold Second Quarter 2020 Financial Results Webcast PR Newswire
Jul-20-20 07:00AM	Akcea Appoints New Senior Vice President, Global Medical Affairs PR Newswire
Jul-17-20 03:31PM	Did Hedge Funds Make The Right Call On Ionis Pharmaceuticals, Inc. (IONS) ? Insider Monkey
Jul-09-20 07:00AM	Akcea Announces Appointment of New Chief Medical Officer PR Newswire
Jul-07-20 07:05AM	Ionis Pharmaceuticals to hold neurology franchise webcast PR Newswire
Jun-17-20 07:00AM	Akcea Therapeutics to Present at the BMO 2020 Prescriptions for Success Healthcare Conference PR Newswire
Jun-16-20 09:48PM	Hedge Funds Arent Crazy About Ionis Pharmaceuticals, Inc. (IONS) Anymore Insider Monkey
Jun-09-20 07:00AM	Akcea Appoints New Senior Vice President, Business Development and Corporate Strategy PR Newswire
Jun-05-20 07:05AM	Ionis Pharmaceuticals to present at upcoming virtual investor conferences PR Newswire
May-29-20 07:03AM	Got $3,000? Here Are 3 Great Biotech Stocks to Buy Right Now Motley Fool
01:50AM	Edited Transcript of IONS earnings conference call or presentation 6-May-20 3:30pm GMT Thomson Reuters StreetEvents
May-28-20 04:05PM	Ionis Pharmaceuticals to host 2020 virtual annual meeting of stockholders PR Newswire
07:00AM	Akcea and Ionis Announce Publication of Long-Term Clinical Data of TEGSEDI® in Patients with Polyneuropathy Driven by Hereditary Transthyretin Amyloidosis Demonstrating Sustained Improvements and Even Greater Stabilization in Patients Starting Earlier Treatment GlobeNewswire
May-19-20 09:07AM	Estimating The Intrinsic Value Of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Simply Wall St.
May-18-20 07:00AM	Akcea Announces Appointment of New Chief Financial Officer PR Newswire
May-14-20 04:05PM	Akcea Announces Approval for Reimbursement of TEGSEDI® (inotersen) in Spain for Treatment of Hereditary Transthyretin Amyloidosis with Polyneuropathy PR Newswire
May-13-20 08:00AM	Akcea Therapeutics Canada Confirms Letter of Intent with Pan-Canadian Pharmaceutical Alliance for TEGSEDI (inotersen injection) CNW Group
May-08-20 06:03AM	Maintaining Our $58 FVE for Ionis Following In-Line Q1; Significant Year for Pipeline Advancement Morningstar
May-07-20 07:00AM	Akcea Expands Leadership Team with Appointment of Carla Poulson as Senior Vice President and Chief Human Resources Officer PR Newswire -5.75%
01:31AM	Ionis Pharmaceuticals, Inc. (IONS) Q1 2020 Earnings Call Transcript Motley Fool
May-06-20 09:45AM	Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Misses Revenue Estimates Zacks
07:00AM	Ionis reports first quarter 2020 financial results and recent business achievements PR Newswire
May-05-20 04:05PM	Akcea Reports Financial Results and Highlights for First Quarter 2020 PR Newswire
May-01-20 07:05AM	Ionis Pharmaceuticals to host 2020 virtual annual meeting of stockholders PR Newswire

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It is involved in developing neurology products that include Tominersen for Huntington's diseases; Tofersen for amyotrophic lateral sclerosis (ALS); IONIS-MAPTRx for Alzheimer's diseases; IONIS-C9Rx for genetic from ALS; ION859 for Parkinson's disease; and IONIS-DNM2-2.5Rx for centronuclear myopathy. The company is also developing severe and rare disease products, such as AKCEA-TTR-LRx for transthyretin amyloidosis and IONIS-GHR-LRx for acromegaly; IONIS-PKK-LRx for hereditary angioedema; IONIS-TMPRSS6-LRx for beta-thalassemia and iron toxicity; IONIS-ENAC-2.5Rx for cystic fibrosis; and ION357 for retinitis pigmentosa. In addition, its cardio metabolic and renal drugs include AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx for cardiovascular diseases; AKCEA-ANGPTL3-LRx for cardio metabolic disorders; IONIS-GCGRRx for type 2 diabetes; IONIS-AGT-LRX for the treatment of resistant hyper tension; IONIS-FXI-LRx for clotting disorders; IONIS-AZ4-2.5-LRx for cardiovascular diseases; and ION839 for nonalcoholic steatohepatitis. Further, the company develops products for oncology that include IONIS-AR-2.5Rx and danvatirsen for cancers; IONIS-HBVRx and IONIS-HBV-LRx for hepatitis B virus infection; and IONIS-FB-LRx for compliment meditated disease. It has a collaboration agreement with AstraZeneca; Biogen Inc.; and Roche. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Monia Brett P	Chief Executive Officer	Mar 01	Sale	54.28	236	12,809	50,114	Mar 02 08:22 PM
CROOKE STANLEY T	Exec Chairman of the Board	Jan 26	Sale	63.74	28,333	1,805,812	2,021	Jan 28 07:22 PM
O'NEIL PATRICK R.	EVP & General Counsel	Jan 25	Sale	63.50	5,324	338,074	26,502	Jan 27 05:35 PM
CROOKE STANLEY T	Exec Chairman of the Board	Jan 22	Sale	61.68	40,000	2,467,000	494,391	Jan 25 08:24 PM
CROOKE STANLEY T	Exec Chairman of the Board	Jan 21	Sale	61.20	35,000	2,142,117	534,391	Jan 25 08:24 PM
CROOKE STANLEY T	Exec Chairman of the Board	Jan 15	Option Exercise	0.00	4,371	0	4,545	Jan 20 07:12 PM
CROOKE STANLEY T	Exec Chairman of the Board	Jan 15	Option Exercise	0.00	47,257	0	49,278	Jan 20 07:12 PM
BENNETT C FRANK	Chief Scientific Officer	Jan 15	Option Exercise	0.00	15,520	0	47,996	Jan 20 07:08 PM
Geary Richard S	EVP, Chief Development Offc	Jan 15	Option Exercise	0.00	17,598	0	47,904	Jan 20 07:06 PM
HOUGEN ELIZABETH L	EVP, Finance & CFO	Jan 15	Option Exercise	0.00	17,151	0	49,646	Jan 20 07:04 PM
Monia Brett P	Chief Executive Officer	Jan 15	Option Exercise	0.00	34,823	0	63,702	Jan 20 07:02 PM
O'NEIL PATRICK R.	EVP & General Counsel	Jan 15	Option Exercise	0.00	16,504	0	37,682	Jan 20 07:00 PM
PARSHALL B LYNNE	Director	Jan 15	Option Exercise	0.00	10,655	0	68,119	Jan 20 06:59 PM
Schneider Eugene	EVP, Chf Clinical Develop Offc	Jan 15	Option Exercise	0.00	7,503	0	9,621	Jan 20 06:55 PM
Swayze Eric	EVP, Research	Jan 15	Option Exercise	0.00	8,944	0	14,051	Jan 20 06:53 PM
Geary Richard S	EVP, Chief Development Offc	Jan 13	Sale	59.50	141	8,390	30,306	Jan 15 05:55 PM
Swayze Eric	EVP, Research	Jan 05	Sale	55.99	195	10,918	5,107	Jan 06 09:23 PM
PARSHALL B LYNNE	Director	Dec 23	Sale	60.00	10,000	600,000	57,464	Dec 28 05:29 PM
CROOKE STANLEY T	Exec Chairman of the Board	Dec 17	Sale	50.50	1,407	71,054	174	Dec 17 07:42 PM
CROOKE STANLEY T	Exec Chairman of the Board	Dec 15	Sale	49.78	39,000	1,941,225	600,391	Dec 17 07:42 PM
CROOKE STANLEY T	Exec Chairman of the Board	Dec 07	Sale	51.67	11,000	568,351	639,391	Dec 09 08:14 PM
BENNETT C FRANK	Chief Scientific Officer	Dec 04	Option Exercise	39.87	7,947	316,847	40,423	Dec 08 08:49 PM
Monia Brett P	Chief Executive Officer	Dec 04	Option Exercise	39.87	23,840	950,501	52,719	Dec 08 08:51 PM
Monia Brett P	Chief Executive Officer	Dec 04	Sale	51.04	23,840	1,216,794	28,879	Dec 08 08:51 PM
BENNETT C FRANK	Chief Scientific Officer	Dec 04	Sale	51.04	7,947	405,615	32,476	Dec 08 08:49 PM
Monia Brett P	Chief Executive Officer	Dec 02	Option Exercise	39.87	21,160	843,649	50,039	Dec 04 08:49 PM
BENNETT C FRANK	Chief Scientific Officer	Dec 02	Option Exercise	39.87	7,053	281,203	39,529	Dec 04 08:53 PM
BENNETT C FRANK	Chief Scientific Officer	Dec 02	Sale	51.32	7,053	361,960	32,476	Dec 04 08:53 PM
Monia Brett P	Chief Executive Officer	Dec 02	Sale	51.32	21,160	1,085,931	28,879	Dec 04 08:49 PM
CROOKE STANLEY T	Exec Chairman of the Board	Nov 25	Option Exercise	39.87	12,990	517,911	15,011	Nov 30 06:48 PM
HOUGEN ELIZABETH L	EVP, Finance & CFO	Nov 25	Option Exercise	39.87	21,680	864,382	54,175	Nov 30 06:49 PM
PARSHALL B LYNNE	Director	Nov 25	Option Exercise	39.87	3,590	143,133	71,054	Nov 30 06:44 PM
Geary Richard S	EVP, Development	Nov 25	Option Exercise	39.87	11,920	475,250	42,367	Nov 30 06:46 PM
PARSHALL B LYNNE	Director	Nov 25	Sale	50.05	3,590	179,680	67,464	Nov 30 06:44 PM
HOUGEN ELIZABETH L	EVP, Finance & CFO	Nov 25	Sale	50.05	21,680	1,085,084	32,495	Nov 30 06:49 PM
CROOKE STANLEY T	Exec Chairman of the Board	Nov 25	Sale	50.05	12,990	650,150	2,021	Nov 30 06:48 PM
Geary Richard S	EVP, Development	Nov 25	Sale	50.05	11,920	596,596	30,447	Nov 30 06:46 PM
PARSHALL B LYNNE	Director	Nov 24	Option Exercise	39.87	710	28,308	68,174	Nov 25 06:56 PM
Geary Richard S	EVP, Development	Nov 24	Option Exercise	39.87	2,380	94,891	32,827	Nov 25 06:58 PM
HOUGEN ELIZABETH L	EVP, Finance & CFO	Nov 24	Option Exercise	39.87	4,320	172,238	36,815	Nov 25 07:02 PM
CROOKE STANLEY T	Exec Chairman of the Board	Nov 24	Option Exercise	39.87	2,590	103,263	4,611	Nov 25 07:04 PM
CROOKE STANLEY T	Exec Chairman of the Board	Nov 24	Sale	50.83	2,590	131,650	2,021	Nov 25 07:04 PM
HOUGEN ELIZABETH L	EVP, Finance & CFO	Nov 24	Sale	50.83	4,320	219,586	32,495	Nov 25 07:02 PM
Geary Richard S	EVP, Development	Nov 24	Sale	50.83	2,380	120,975	30,447	Nov 25 06:58 PM
PARSHALL B LYNNE	Director	Nov 24	Sale	50.82	710	36,082	67,464	Nov 25 06:56 PM
PARSHALL B LYNNE	Director	Nov 23	Option Exercise	39.87	3,200	127,584	70,664	Nov 25 06:56 PM
Geary Richard S	EVP, Development	Nov 23	Option Exercise	39.87	10,700	426,609	41,147	Nov 25 06:58 PM
HOUGEN ELIZABETH L	EVP, Finance & CFO	Nov 23	Option Exercise	39.87	19,000	757,530	45,620	Nov 25 07:02 PM
CROOKE STANLEY T	Exec Chairman of the Board	Nov 23	Option Exercise	39.87	500	19,935	2,081	Nov 25 07:04 PM
CROOKE STANLEY T	Exec Chairman of the Board	Nov 23	Option Exercise	39.87	11,600	462,492	13,621	Nov 25 07:04 PM
CROOKE STANLEY T	Exec Chairman of the Board	Nov 23	Sale	50.00	500	25,000	1,581	Nov 25 07:04 PM
CROOKE STANLEY T	Exec Chairman of the Board	Nov 23	Sale	50.11	11,600	581,276	2,021	Nov 25 07:04 PM
HOUGEN ELIZABETH L	EVP, Finance & CFO	Nov 23	Sale	50.11	19,000	952,090	32,495	Nov 25 07:02 PM
Geary Richard S	EVP, Development	Nov 23	Sale	50.11	10,700	536,177	30,447	Nov 25 06:58 PM
PARSHALL B LYNNE	Director	Nov 23	Sale	50.12	3,200	160,384	67,464	Nov 25 06:56 PM
BENNETT C FRANK	Chief Scientific Officer	Nov 03	Option Exercise	39.87	15,000	598,050	47,476	Nov 05 08:26 PM
BENNETT C FRANK	Chief Scientific Officer	Nov 03	Sale	46.77	15,000	701,600	32,476	Nov 05 08:26 PM
KLEIN JOSEPH III	Director	Oct 20	Sale	46.86	2,889	135,386	13,794	Oct 22 05:36 PM
Hayden Michael R	Director	Oct 15	Option Exercise	0.00	1,778	0	5,334	Oct 19 05:50 PM
Reikes Peter N	Director	Oct 15	Option Exercise	0.00	1,778	0	5,334	Oct 19 05:46 PM
CROOKE STANLEY T	Exec Chairman of the Board	Sep 22	Sale	50.41	50,000	2,520,460	650,391	Sep 23 06:44 PM
CROOKE STANLEY T	Exec Chairman of the Board	Sep 21	Sale	50.18	2,000	100,360	1,581	Sep 23 06:44 PM
WENDER JOSEPH H	Director	Sep 16	Option Exercise	20.71	22,500	465,863	88,305	Sep 18 05:45 PM
Monia Brett P	Chief Executive Officer	Sep 01	Sale	53.70	314	16,862	28,879	Sep 02 07:01 PM
LOSCALZO JOSEPH	Director	Jul 06	Option Exercise	0.00	667	0	17,308	Jul 06 05:49 PM
KLEIN JOSEPH III	Director	Jul 06	Option Exercise	0.00	667	0	16,683	Jul 06 05:32 PM
Castleman Breaux	Director	Jul 06	Option Exercise	0.00	667	0	19,183	Jul 06 05:30 PM
WENDER JOSEPH H	Director	Jul 06	Option Exercise	0.00	667	0	65,805	Jul 06 05:26 PM
BERTHELSEN SPENCER R	Director	Jul 06	Option Exercise	0.00	667	0	100,983	Jul 06 05:25 PM
MUTO FREDERICK T	Director	Jul 06	Option Exercise	0.00	667	0	31,683	Jul 06 05:23 PM
LOSCALZO JOSEPH	Director	Jul 02	Option Exercise	0.00	889	0	16,641	Jul 06 05:49 PM
PARSHALL B LYNNE	Director	Jul 02	Option Exercise	0.00	889	0	67,464	Jul 06 05:47 PM
KLEIN JOSEPH III	Director	Jul 02	Option Exercise	0.00	889	0	16,016	Jul 06 05:32 PM
Castleman Breaux	Director	Jul 02	Option Exercise	0.00	889	0	18,516	Jul 06 05:30 PM
WENDER JOSEPH H	Director	Jul 02	Option Exercise	0.00	889	0	65,138	Jul 06 05:26 PM
BERTHELSEN SPENCER R	Director	Jul 02	Option Exercise	0.00	889	0	100,316	Jul 06 05:25 PM
MUTO FREDERICK T	Director	Jul 02	Option Exercise	0.00	889	0	31,016	Jul 06 05:23 PM
Hayden Michael R	Director	Jul 01	Option Exercise	0.00	1,778	0	3,556	Jul 06 06:48 PM
HERMAN JOAN E	Director	Jul 01	Option Exercise	0.00	1,778	0	5,334	Jul 06 05:51 PM
LOSCALZO JOSEPH	Director	Jul 01	Option Exercise	0.00	2,444	0	15,752	Jul 06 05:49 PM
PARSHALL B LYNNE	Director	Jul 01	Option Exercise	0.00	1,778	0	66,575	Jul 06 05:47 PM
KLEIN JOSEPH III	Director	Jul 01	Option Exercise	0.00	2,444	0	15,127	Jul 06 05:32 PM
Castleman Breaux	Director	Jul 01	Option Exercise	0.00	2,444	0	17,627	Jul 06 05:30 PM
Reikes Peter N	Director	Jul 01	Option Exercise	0.00	1,778	0	3,556	Jul 06 05:28 PM
WENDER JOSEPH H	Director	Jul 01	Option Exercise	0.00	2,444	0	64,249	Jul 06 05:26 PM
BERTHELSEN SPENCER R	Director	Jul 01	Option Exercise	0.00	2,444	0	99,427	Jul 06 05:25 PM
MUTO FREDERICK T	Director	Jul 01	Option Exercise	0.00	2,444	0	30,127	Jul 06 05:23 PM
MUTO FREDERICK T	Director	Jun 30	Option Exercise	9.22	15,000	138,300	27,683	Jul 02 05:11 PM
Castleman Breaux	Director	Jun 25	Option Exercise	26.66	10,000	266,600	25,183	Jun 29 09:47 PM
BENNETT C FRANK	EVP, Chief Scientific Officer	Jun 25	Option Exercise	39.87	15,000	598,050	47,364	Jun 29 09:47 PM
CROOKE STANLEY T	Exec Chairman of the Board	Jun 25	Sale	60.11	9,914	595,907	2,021	Jun 26 07:47 PM
BENNETT C FRANK	EVP, Chief Scientific Officer	Jun 25	Sale	59.77	15,000	896,505	32,364	Jun 29 09:47 PM
Castleman Breaux	Director	Jun 25	Sale	60.00	10,000	600,000	15,183	Jun 29 09:47 PM
CROOKE STANLEY T	Exec Chairman of the Board	Jun 24	Sale	58.80	5,000	294,000	11,935	Jun 26 07:47 PM
BERTHELSEN SPENCER R	Director	Jun 23	Option Exercise	9.22	15,000	138,300	111,983	Jun 25 07:28 PM
BERTHELSEN SPENCER R	Director	Jun 23	Sale	58.76	15,000	881,400	96,983	Jun 25 07:28 PM
CROOKE STANLEY T	Exec Chairman of the Board	Jun 19	Sale	58.33	10,000	583,250	16,935	Jun 19 07:03 PM
CROOKE STANLEY T	Exec Chairman of the Board	Jun 17	Sale	58.25	2,000	116,500	3,581	Jun 19 07:03 PM
CROOKE STANLEY T	Exec Chairman of the Board	Jun 17	Sale	57.90	15,000	868,521	26,935	Jun 19 07:03 PM
HERMAN JOAN E	Director	Jun 10	Option Exercise	0.00	3,556	0	3,556	Jun 17 08:15 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience